Literature DB >> 10720133

Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells.

U Kordes1, D Krappmann, V Heissmeyer, W D Ludwig, C Scheidereit.   

Abstract

The pleiotropic transcription factor NF-kappaB controls cellular apoptotic and growth processes and increasing evidence suggests a role in tumorigenesis. We describe here that constitutively activated NF-kappaB complexes are found in the vast majority (39 out of 42 samples) of childhood acute lymphoblastic leukemia (ALL) without any subtype restriction. Electrophoretic shift analysis further demonstrates that these complexes are composed of p50-p50 and p65-p50 dimers. Proteasome inhibition in primary ALL cultures results in a hyperphosphorylated form of IkappaBalpha, indicating that activation of upstream kinases, which trigger IkappaBalpha degradation, has led to nuclear translocation of NF-kappaB. Careful inhibition of cellular proteolytic activities is of importance when analyzing extracts from primary ALL cells. Degradation of p65 and other proteins in ALL samples could be specifically suppressed by alpha-1 antitrypsin. Constitutive NF-kappaB activation is thus a common characteristic of childhood ALL and strongly suggests a critical role of this factor for leukemia cell survival.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10720133     DOI: 10.1038/sj.leu.2401705

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  63 in total

1.  CDNA microarray analysis of chronic myeloid leukemia.

Authors:  Huiyu Li; Shenghua Jie; Ping Zou; Guolin Zou
Journal:  Int J Hematol       Date:  2002-05       Impact factor: 2.490

Review 2.  Molecular pharmacodynamics in childhood leukemia.

Authors:  R Pieters; M L den Boer
Journal:  Int J Hematol       Date:  2003-12       Impact factor: 2.490

Review 3.  NF-kappaB in pancreatic cancer.

Authors:  Guido M Sclabas; Shuichi Fujioka; Christian Schmidt; Douglas B Evans; Paul J Chiao
Journal:  Int J Gastrointest Cancer       Date:  2003

Review 4.  Update on developmental therapeutics for acute lymphoblastic leukemia.

Authors:  Malcolm A Smith
Journal:  Curr Hematol Malig Rep       Date:  2009-07       Impact factor: 3.952

Review 5.  Phosphorylation/de-phosphorylation in specific sites of tumor suppressor WWOX and control of distinct biological events.

Authors:  Shenq-Shyang Huang; Nan-Shan Chang
Journal:  Exp Biol Med (Maywood)       Date:  2018-01-08

6.  Bortezomib combined with standard induction chemotherapy in Japanese children with refractory acute lymphoblastic leukemia.

Authors:  Akihiro Iguchi; Yuko Cho; Minako Sugiyama; Yukayo Terashita; Tadashi Ariga; Yosuke Hosoya; Shinsuke Hirabayashi; Atsushi Manabe; Keisuke Hara; Tetsuya Aiba; Tsugumi Shiokawa; Hiroko Tada; Norihiro Sato
Journal:  Int J Hematol       Date:  2017-04-11       Impact factor: 2.490

7.  Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia.

Authors:  Takaomi Sanda; Xiaoyu Li; Alejandro Gutierrez; Yebin Ahn; Donna S Neuberg; Jennifer O'Neil; Peter R Strack; Christopher G Winter; Stuart S Winter; Richard S Larson; Harald von Boehmer; A Thomas Look
Journal:  Blood       Date:  2009-12-09       Impact factor: 22.113

8.  Aberrant constitutive activation of nuclear factor kappaB in glioblastoma multiforme drives invasive phenotype.

Authors:  Baisakhi Raychaudhuri; Yulong Han; Tao Lu; Michael A Vogelbaum
Journal:  J Neurooncol       Date:  2007-05-04       Impact factor: 4.130

9.  NF-kappaB controls growth of glioblastomas/astrocytomas.

Authors:  Denise Smith; Takeshi Shimamura; Stephanie Barbera; Bruce E Bejcek
Journal:  Mol Cell Biochem       Date:  2007-09-09       Impact factor: 3.396

10.  IKKalpha, IKKbeta, and NEMO/IKKgamma are each required for the NF-kappa B-mediated inflammatory response program.

Authors:  Xiang Li; Paul E Massa; Adedayo Hanidu; Gregory W Peet; Patrick Aro; Ann Savitt; Sheenah Mische; Jun Li; Kenneth B Marcu
Journal:  J Biol Chem       Date:  2002-09-06       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.